ASCO Studies Bolster Agendia's Marketing Plans for ColoPrint and MammaPrint

Based on data Agendia presented on its ColoPrint and MammaPrint assays at ASCO, the company is planning to launch its colorectal cancer test by 2010 in Europe and push for broader adoption of its breast cancer test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.